Investing.com -- Shares of Soligenix (NASDAQ: SNGX) climbed 2.9% following the company’s announcement of promising results for its skin cancer treatment, HyBryteTM, in treating cutaneous T-cell ...

Watch here: Soligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding ...

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell ...

The trial will test MB-105 in up to 46 patients with relapsed or refractory CD5-positive cutaneous T-cell lymphoma or peripheral T-cell lymphoma.

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Interim Data from IIS Study Shows 75% Response Rate and Three ...

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Soligenix (SNGX) announced interim results from the ongoing open-label, investigator-initiated study evaluating extended HyBryte treatment for ...

A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

PRESENTED at EBMT 2025 Annual Meeting, a new study explored the long-term effectiveness of chimeric antigen receptor (CAR)-T cell cocktail therapy for patients with relapsed/refractory diffuse large B ...